A Phase 3, randomized, placebo-controlled, 12-week, double-blind study, plus a non-controlled extension treatment period, to assess efficacy and safety of fezolinetant, a neurokin-3 receptor antagonist, in women with moderate-to-severe vasomotor symptoms associated with menopause

被引：0

作者：

Johnson, Kimball ^{[1
]}

Lademacher, Christopher ^{[3
]}

Nappi, Rossella E. ^{[8
]}

Neal-Perry, Genevieve ^{[4
]}

Shapiro, Marla ^{[5
]}

Stute, Petra ^{[6
]}

Thurston, Rebecca C. ^{[7
]}

Wolfman, Wendy ^{[5
]}

English, Marci ^{[3
]}

Franklin, Catherine ^{[3
]}

Lee, Misun ^{[3
]}

Santoro, Nanette ^{[2
]}

机构：

[1] iRes Atlanta LLC, Decatur, GA USA

[2] CU, Sch Med, Aurora, CO USA

[3] Astellas Pharma Global Dev Inc, Northbrook, IL USA

[4] UNC, Sch Med, Chapel Hill, NC USA

[5] Univ Toronto, Toronto, ON, Canada

[6] Univ Spital Bern, Inselspital, Bern, Switzerland

[7] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA

[8] Univ Pavia, IRCCS S Matteo, Pavia, Italy

来源：

MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY | 2021年 / 28卷 / 12期

关键词：

D O I：

暂无

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

S-13

引用

页码：1450 / 1450

页数：1

共 50 条

[1] A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause
Fraser, Graeme L.
Lederman, Samuel
Waldbaum, Arthur
Kroll, Robin
Santoro, Nanette
Lee, Misun
Skillern, Laurence
Ramael, Steven
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2020, 27 (04): : 382 - 392
[2] Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safety
Archer, David F.
Dupont, Caroline M.
Constantine, Ginger D.
Pickar, James H.
Olivier, Sophie
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2009, 200 (03) : 238.e1 - 238.e10
[3] Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study
Lederman, Samuel
Ottery, Faith
Cano, Antonio
Santoro, Nanette
Shapiro, Marla
Stute, Petra
Thurston, Rebecca C.
English, Marci
Franklin, Catherine
Lee, Misun
Neal-Perry, Genevieve
LANCET, 2023, 401 (10382): : 1091 - 1102
[4] The Neurokinin 3 Receptor Antagonist, Fezolinetant, is Effective in Treatment of Menopausal Vasomotor Symptoms: A Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Study
Fraser, Graeme
Lederman, Samuel
Waldbaum, Arthur
Lee, Misun
Skillern, Laurence
Ramael, Steven
JOURNAL OF WOMENS HEALTH, 2019, 28 (06) : 15 - 15
[5] Dupilumab Monotherapy in Adults with Moderate-to-Severe Atopic Dermatitis: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study
Bieber, Thomas R. M.
Thaci, Diamant
Graham, Neil
Pirozzi, Gianluca
Teper, Ariel
Ren, Haobo
Radin, Allen
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2014, 133 (02) : AB404 - AB404
[6] A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause
Archer, David F.
Seidman, Larry
Constantine, Ginger D.
Pickar, James H.
Olivier, Sophie
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2009, 200 (02) : 172.e1 - 172.e10
[7] Efficacy and Safety of Baricitinb in a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study in Pediatric Patients with Moderate-to-Severe Atopic Dermatitis
Torrelo, A.
Rewerska, B.
Paller, Amy
Prakash, A.
Zhu, D.
Pontes, M.
Wu, Wen-Shuo
Eichenfield, Lawrence F.
Boecker, Ulrike
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 99 - 99
[8] Efficacy and safety of vunakizumab in moderate-to-severe chronic plaque psoriasis: A randomized, double-blind, placebo-controlled phase 3 trial
Yan, Kexiang
Li, Fuqiu
Bi, Xiaodong
Han, Ling
Zhang, Zhenghua
Chen, Rixin
Li, Yuye
Zhang, Litao
Wang, Xiaohua
Li, Linfeng
Lu, Jianyun
Xu, Ai'e
Yang, Sen
Lu, Yan
Sun, Jianfang
Li, Zhiming
Zhu, Xiaohong
Jiang, Meiying
Zhang, Siping
Wang, Wenqing
Li, Yanling
Meng, Zudong
Li, Hongyi
Mou, Kuanhou
Han, Xiuping
Li, Shanshan
Chen, Aijun
Li, Xin
Liu, Donghua
Zhang, Chunlei
Ji, Chao
Wang, Yu
Cheng, Hao
Cui, Xiaojing
Yao, Xiaoyan
Bai, Xiaoyan
Dong, Guangchao
Xu, Jinhua
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2025, 92 (01) : 92 - 99
[9] A phase 3, randomized, placebo- controlled, double-blind study to investigate the long-term safety and tolerability of fezolinetant in women seeking treatment for vasomotor symptoms associated with menopause (SKYLIGHT 4)
Neal-Perry, Genevieve
Cano, Antonio
Lederman, Samuel
Nappi, Rossella E.
Santoro, Nanette F.
Wolfman, Wendy
English, Marci
Franklin, Catherine
Zhao, Jun
Ottery, Faith D.
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2022, 29 (12): : 1453 - 1453
[10] Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a phase 3, randomized, double-blind, placebo-controlled, multicenter trial
Archer, David F.
Goldstein, Steven R.
Simon, James A.
Waldbaum, Arthur S.
Sussman, Steven A.
Altomare, Corrado
Zhu, Julie
Yoshida, Yuki
Schaffer, Sam
Soulban, Graziella
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2019, 26 (06): : 611 - 621

← 1 2 3 4 5 →